Certified Global Research Member

Key Questions Answered

Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the key challenges in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major playersâ€™ financial performance.
Evaluate strategies adopted by major players.
Recommendations

Why Choose Market Research Future?

Vigorous research methodologies for specific market.
Knowledge partners across the globe
Large network of partner consultants.
Ever-increasing/ Escalating data base with quarterly monitoring of various markets
Trusted by fortune 500 companies/startups/ universities/organizations
Large database of 5000+ markets reports.
Effective and prompt pre- and post-sales support.

Atrial Fibrillation Systems Companies

Atrial fibrillation (AFib) is a common heart rhythm disorder characterized by irregular and often rapid heartbeats. Treatment and management of AFib involve various approaches, including medications, lifestyle modifications, and medical devices.

Atrial Fibrillation Key Companies Latest Atrial Fibrillation Companies Update

November 2023: In patients with atrial fibrillation with rapid ventricular rate (AFib-RVR), etripamil nasal spray demonstrated rapid and statistically superior ventricular rate reduction and improved symptom relief compared to placebo, according to positive Phase 2 data released today by Milestone Pharmaceuticals Inc. The safety and tolerability findings from the safety population consisting of 56 patients are comparable to those reported in Milestone's Phase 3 paroxysmal supraventricular tachycardia (PSVT) program, which is significantly larger in scale. Concurrently with their Featured Science presentation at the American Heart Association (AHA) Scientific Sessions 2023 and publication in Circulation: Arrhythmia and Electrophysiology, the findings were unveiled. Further development of self-administered etripamil for the treatment of AFib-RVR is supported by these findings.

During a Late-Breaking session of the American Heart Association (AHA) meeting in November 2023, Anthos Therapeutics, Inc., a clinical stage company established by Blackstone Life Sciences and focused on developing novel therapies for cardiovascular diseases, disclosed that abelacimab exhibited a substantially reduced occurrence of bleeding events across all primary and secondary endpoints when compared to a direct-oral anticoagulant (DOAC), which is the standard of care. An extension study has been initiated by Anthos Therapeutics to facilitate the transition of patients from rivaroxaban to abelacimab in order to capitalize on the enhanced hemorrhage profile. Anticoagulation therapy aims to heal or prevent thrombosis while minimizing hemostasis disruption. Despite the efficacy of presently accessible anticoagulants in preventing strokes among individuals with atrial fibrillation, the potential for hemorrhaging continues to be a concern.

List of Atrial Fibrillation Key companies in the market

Johnson & Johnson Services Inc.

Abbott

Medtronic Plc

Boston Scientific Corporation

MicroPort Scientific Corporation

Biotronik SE & Co. KG

Koninklijke Philips N.V.

AtriCure Inc.

CardioFocus

Osypka AG

Atrial Fibrillation Systems Market Highlights:

Atrial Fibrillation Systems Market Size

Atrial Fibrillation Systems Market Trends

Atrial Fibrillation Systems Market Analysis

Atrial Fibrillation Systems Market Share

Atrial Fibrillation Systems Market Highlights:

Atrial Fibrillation Systems Market Trends

Atrial Fibrillation Systems Market Analysis

Atrial Fibrillation Systems Market Share

Atrial Fibrillation Systems Companies

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

Tailored for You

Dedicated Research on any specifics segment or region.
Focused Research on specific players in the market.
Custom Report based only on your requirements.
Flexibility to add or subtract any chapter in the study.
Historic data from 2014 and forecasts outlook till 2040.
Flexibility of providing data/insights in formats (PDF, PPT, Excel).
Provide cross segmentation in applicable scenario/markets.